The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

US FDA approves Verastem’s Avmapki Fakzynja combo therapy to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer: Boston Saturday, May 10, 2025, 13:00 Hrs ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer ...

May 8 (Reuters) - The U.S. Food and Drug Administration has approved Verastem's (VSTM.O), opens new tab combination therapy for patients with a rare type of ovarian cancer who have received prior ...

Matthew Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health ...